Table 1 Clinical data of the 30 untreated CLL patients tested for Ca2+ entry and dichotomized into CE+ (high constitutive Ca²⁺ entry [CE]) and CE- (low/normal CE levels) and of the whole CLL cohort (n = 74), dichotomized according to the level of STIM1 located in the plasma membrane (STIM1_PM) in high and low

Age diagnosis (years), mean ± SEM

63 ± 3

62 ± 2

NS

63 ± 2

64 ± 2

NS

Age analysis (years)

69 ± 4

67 ± 2

NS

70 ± 2

70 ± 2

NS

Sex F:M

4:10

8:8

NS

14:14

16:32

NS

Binet A/B/C

12/2/0

2/12/2

0.0002

13/10/5

31/10/3

NS

Cytogenetic risks, No (%)

NS

NS

 Low (isolated d13q)

6/12 (50%)

8/16 (50%)

13/26 (50%)

21/37 (56.8%)

 Intermediate (tri12, normal karyotype)

6/12 (50%)

5/16 (31%)

9/26 (34.6%)

13/37 (35.1%)

 High (d11q, d17p, complex karyotype)

0/11

(0%)

3/16 (19%)

4/26 (15.4%)

3/37 (8.1%)

IgHV UM:M

0:7

0:10

NS

3:14

3:21

NS

CD38 (> 30%)

1/12

(8%)

4/15 (27%)

NS

7/28 (25%)

6/45 (13.3%)

NS

Lymphocytosis (Giga/L)

30 ± 4

74 ± 12

0.003

57.2 ± 9.2

34.6 ± 3.5

0.05

PFS (median-months)^a

> 150

44

0.001

46

120

0.0007

TFS (median-months)^a

> 150

63

0.003

116

> 120

0.02

LDT (median months)^a

49

22

0.02

24

36

NS